IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BERRUTI, ALFREDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 36.330
AS - Asia 16.325
EU - Europa 11.704
SA - Sud America 3.527
Continente sconosciuto - Info sul continente non disponibili 1.050
AF - Africa 345
OC - Oceania 36
Totale 69.317
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 35.693
SG - Singapore 5.759
CN - Cina 5.048
BR - Brasile 2.915
UA - Ucraina 2.774
HK - Hong Kong 1.907
IT - Italia 1.826
DE - Germania 1.592
VN - Vietnam 1.203
PL - Polonia 980
FI - Finlandia 820
FR - Francia 777
GB - Regno Unito 706
RU - Federazione Russa 700
TR - Turchia 609
BD - Bangladesh 568
IE - Irlanda 520
IN - India 350
CA - Canada 328
AR - Argentina 235
EE - Estonia 191
MX - Messico 154
SE - Svezia 148
ID - Indonesia 147
IQ - Iraq 135
NL - Olanda 135
ZA - Sudafrica 120
JP - Giappone 119
CZ - Repubblica Ceca 113
ES - Italia 95
EC - Ecuador 94
AT - Austria 66
PK - Pakistan 61
SA - Arabia Saudita 61
BE - Belgio 58
CO - Colombia 58
VE - Venezuela 56
MA - Marocco 50
PY - Paraguay 50
UZ - Uzbekistan 49
CL - Cile 48
AE - Emirati Arabi Uniti 36
JM - Giamaica 36
EG - Egitto 32
CH - Svizzera 30
AU - Australia 29
NG - Nigeria 29
KE - Kenya 28
CR - Costa Rica 27
DZ - Algeria 27
LT - Lituania 27
PE - Perù 27
JO - Giordania 24
KZ - Kazakistan 24
UY - Uruguay 23
AZ - Azerbaigian 21
TN - Tunisia 21
PH - Filippine 20
AL - Albania 19
KR - Corea 19
NP - Nepal 19
HN - Honduras 18
IL - Israele 18
LB - Libano 18
EU - Europa 16
PT - Portogallo 16
BO - Bolivia 15
BG - Bulgaria 14
DK - Danimarca 13
PA - Panama 13
RO - Romania 13
TH - Thailandia 11
TT - Trinidad e Tobago 11
ET - Etiopia 10
GT - Guatemala 10
HU - Ungheria 10
IR - Iran 10
TW - Taiwan 10
BB - Barbados 9
KG - Kirghizistan 9
LV - Lettonia 9
MY - Malesia 9
GR - Grecia 8
OM - Oman 8
PS - Palestinian Territory 8
BH - Bahrain 7
DO - Repubblica Dominicana 7
MK - Macedonia 7
CY - Cipro 6
MD - Moldavia 6
NZ - Nuova Zelanda 6
SV - El Salvador 6
MU - Mauritius 5
NO - Norvegia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
SY - Repubblica araba siriana 5
AM - Armenia 4
BY - Bielorussia 4
GE - Georgia 4
Totale 68.204
Salva come PNG Salva come JPEG
Città #
Fairfield 4.233
Woodbridge 3.240
Ashburn 3.051
Singapore 2.968
Houston 2.235
Hong Kong 1.895
Jacksonville 1.885
Seattle 1.748
Cambridge 1.595
Wilmington 1.380
Ann Arbor 1.362
Beijing 1.273
San Jose 1.153
The Dalles 1.082
Warsaw 955
Princeton 881
New York 827
Chandler 728
Los Angeles 668
Council Bluffs 635
Dallas 617
Helsinki 579
Chicago 533
Lauterbourg 490
Dublin 477
Nanjing 473
Istanbul 470
Ho Chi Minh City 412
Munich 301
Buffalo 276
Brescia 274
Des Moines 235
Redondo Beach 226
Hanoi 218
Columbus 216
São Paulo 213
Milan 207
Dearborn 201
Santa Clara 199
Moscow 198
Salt Lake City 193
Tallinn 191
San Diego 190
Nanchang 188
Shanghai 181
San Francisco 157
Boardman 156
Changsha 154
Shenyang 141
London 136
Hebei 133
Orem 125
Turku 116
Tianjin 105
Jinan 94
Rio de Janeiro 92
Tampa 91
Rome 89
Brooklyn 88
Jakarta 88
Tokyo 84
Elk Grove Village 83
Brno 80
Dong Ket 80
Nuremberg 79
Toronto 78
Phoenix 77
Secaucus 75
Montreal 72
Jiaxing 70
Atlanta 69
Hangzhou 69
Stockholm 68
Belo Horizonte 67
Denver 67
Dalmine 66
Johannesburg 60
Chennai 57
Lappeenranta 57
Mexico City 57
Romola 57
Brasília 56
Frankfurt am Main 56
Orange 56
Verona 56
Lancaster 55
Boston 54
Kunming 54
Poplar 54
Da Nang 53
Guangzhou 53
Brussels 52
Kocaeli 51
Zhengzhou 51
Naples 50
Washington 48
Haiphong 47
Paris 47
Baghdad 45
Amsterdam 44
Totale 45.771
Salva come PNG Salva come JPEG
Nome #
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer 794
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 383
Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate 318
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 298
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors 293
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 263
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 258
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 256
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 254
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† 254
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 253
Excess of second tumors in denosumab-treated patients: A metabolic hypothesis 252
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 252
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 251
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 248
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case 232
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 230
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 226
Pros-IT CNR: an Italian prostate cancer monitoring project 225
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 225
Immunotherapy failure in adrenocortical cancer: where next? 224
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy 222
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer 216
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 215
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 213
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 213
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials 212
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 211
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma 211
Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report 208
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy 205
Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy 204
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 203
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer 201
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 200
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) 198
Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower Risk Patients With Early-Stage Breast Cancer? 198
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 197
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report 194
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity 194
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study 193
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 192
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 191
Palbociclib inhibits proliferation of human adrenocortical tumor cells 190
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis 190
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 190
Regression of advanced neuroendocrine tumors among patients receiving placebo 189
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells 187
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 186
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 185
Progression of vertebral fractures in metastatic melanoma and non-small cell lung cancer patients given immune checkpoint inhibitors 183
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 183
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 182
A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report 182
828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS 180
Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease 180
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. 180
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 179
Adjuvant bisphosphonates in patients with breast cancer: Does the potency matter? 178
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. 176
Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response 176
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. 175
Osimertinib in EGFR Mutation–Positive Advanced NSCLC 175
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 175
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? 175
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 174
Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients 173
A current perspective on treatment of adrenocortical carcinoma 172
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs) 172
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? 171
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 171
When should everolimus be administered in the natural history of pancreatic neuroendocrine tumors? 170
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study 169
Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method 169
Serum vitamin D and prostate cancer prognosis: The story continues 169
Exemestane with ovarian suppression in premenopausal breast cancer. 169
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis 168
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 168
Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. 168
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma 167
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 167
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† 167
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 166
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 164
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 164
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma 163
Cisplatin Cytotoxicity in Human Testicular Germ Cell Tumor Cell Lines Is Enhanced by the CDK4/6 Inhibitor Palbociclib 162
Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life. 161
Fat Fraction Extracted from Whole-Body Magnetic Resonance (WB-MR) in Bone Metastatic Prostate Cancer: Intra- and Inter-Reader Agreement of Single-Slice and Volumetric Measurements 160
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report 159
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance 159
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 158
An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: A case report 157
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects 157
Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design 156
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma 155
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 155
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 155
Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma 155
Aspergillosis superinfection as a cause of death of crizotinib-induced interstitial lung disease successfully treated with high-dose corticosteroid therapy 153
Totale 20.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 340.936
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 340.936
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.229 0 702 93 213 50 182 214 234 194 349 267 731
2022/20232.586 497 83 74 178 191 712 10 212 347 44 115 123
2023/20243.948 180 96 316 217 207 696 109 145 1.039 118 48 777
2024/202510.895 98 74 98 1.510 1.168 737 591 293 1.088 803 2.697 1.738
2025/202620.305 1.636 2.770 1.934 3.138 1.553 1.223 2.697 784 1.253 1.786 954 577
2026/20271.616 852 764 0 0 0 0 0 0 0 0 0 0
Totale 69.317